Non ST-elevation acute coronary syndromes: New Zealand management guidelines

New Zealand Medical Journal

Volumn 118, Issue 1223, 2005, Pages

  Ko, Albert ^a,s   Hamer, Andrew ^b,s   Kerr, Andrew ^a,s   Wong, Brandon ^c,s   Renner, Charles ^d,s   Sebastian, Cherian ^e,s   Wong, Cheuk Kit ^f,s   Ellis, Chris ^g,s   Nunn, Chris ^h,s   Wade, Clyde ^h,s   Curtis, Elana ^i,s   Grigor, Euan G ^j,s   Wilkins, Gerry ^k,s   Armstrong, Guy ^l,s   Ikram, Hamid ^m,s   Hart, Hamish ^l,s   White, Harvey ^g,s   Williams, Helen ^n,s   Patel, Hitesh ^l,s   Crozier, Ian ^m,s   Elliott, John ^m,s   French, John ^g,s   Lambie, Laura ^n,s   Abernathy, Malcolm ^o,s   Simmonds, Mark ^p,s   Webster, Mark ^g,s   Tansor, Paul ^q,s   Astridge, Penny ^b,s   Matsis, Phil ^p,s   Luke, Richard ^r,s   Mann, Stewart ^p,s   Al Khairulla, Younis ^i,s   Devlin, Gerry ^h,s   more..

^a Middle Hospital   (New Zealand)

^b Nelson Malborough District Health Board   (New Zealand)

^c WHANGAREI HOSPITAL   (New Zealand)

^d Kew Hospital   (New Zealand)

^e TARANAKI BASE HOSPITAL   (New Zealand)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h WAIKATO HOSPITAL   (New Zealand)

ⁱ The Old Cottage Hospital ^*

^j The Cottage   (United Kingdom)

^k DUNEDIN HOSPITAL   (New Zealand)

^l NORTH SHORE HOSPITAL   (New Zealand)

^m CHRISTCHURCH HOSPITAL   (New Zealand)

ⁿ MINISTRY OF HEALTH   (New Zealand)

^o Wakefield Hospital   (New Zealand)

^p WELLINGTON HOSPITAL   (New Zealand)

^q Midcentral   (New Zealand)

^r Napier Hospital   (New Zealand)

^s The New Zealand Branch of the Cardiac Society of Australia and New Zealand   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIEMETIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; NATRIURETIC FACTOR; OPIATE; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TIROFIBAN; UNINDEXED DRUG;

ARTICLE; AUSTRALIA; BLEEDING; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; NEW ZEALAND; PAIN; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 27744464001     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Aroney C, Boyden AN, Jelinek MV, et al. Management of unstable angina: guidelines - 2000. Med J Aust 2000;17(Suppl):S65-S88.
2. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-74.
4. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III registry ECG ancillary study. J Am Coll Cardiol 1997;30:133-40.
5. French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart 2004;90:99-106.
6. Hyde TA, French JK, Wong CK, et al. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. Am J Cardiol 1999;84:379-85.
7. Lindahl B, Venge P, Wallentin L, et al. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93:1651-7.
8. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333-41.
9. Stubbs P, Collinson P, Moseley D, et al. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. Br Med J 1996;313:262-4.
10. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
11. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
12. Newby LK, Kaplan AL, Granger BB, et al. Comparison of cardiac troponin I versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. Am J Cardiol 2000;85:801-5.
13. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
14. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-8.
15. Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998;98:1853-9.
16. Hamm CW. Cardiac biomarkers for rapid evaluation of chest pain. Circulation 2001;104:1454-6.
17. Wu AH, Apple FS, Gibler WB, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
18. Perna ER, Macin SM, Parras JI, et al. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002;143:814-20.
19. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-13.
20. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36:1812-7.
21. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-62.
22. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
23. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
24. Mazzone A, De Servi S, Ricevuti G, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993;88:358-63.
25. Damas JK, Waehre T, Yndestad A, et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003;107:2670-6.
26. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
27. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003;107:2109-14.
28. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809-40.
29. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-12.
30. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
31. Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-9.
32. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/ non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
33. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Erratum available from: http://bmj.com/cgi/content/full/324/7329/71/DC2 Br Med J 2002;324:71-86.
34. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7.
35. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
36. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
37. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized Controlled Trial. JAMA 2002;288:2411-20.
38. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
39. Mahoney EM, Mehta S, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndrome: Results from PCI-CURE [abstract]. Circulation 2003:108:IV-576-2625.
40. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: results from the CURE trial [abstract]. Circulation 2003;108:IV-417.
41. Beinart S, Kolm P, Veledar E, et al. Short and long-term cost effectiveness of early and substantial dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: Results from CREDO [abstract]. Circulation 2003;108:IV-775-3495.
42. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/ IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
43. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767-71.
44. Janzon M, Levin LA, Swahn E, et al. Cost-effectiveness of an invasive strategy in unstable coronary artery disease: results from the FRISC II invasive trial. Eur Heart J 2002;23:31-40.
45. Szucs TD, Meyer BJ, Kiowski W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS Trial. Eur Heart J 1999;20:1253-60.
46. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851-8.
47. Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the Platelet Activity Extinction in Non-Q-Wave Myocardial Infarction With Aspirin, Clopidogrel, and Eptifibatide (PEACE) study. J Am Coll Cardiol 2004;43:162-8.
48. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
49. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial [Erratum in: JAMA. 2004;292:1178]. JAMA 2004;292:55-64.
50. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
51. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
52. The European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
53. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
54. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? [commentary]. Lancet 2003;362:755-7.
55. Fox K, Poole-Wilson P, Henderson R, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
56. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290:1593-9.
57. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23.
58. Mann S. Diagnostic electrocardiography (ECG) and related services in New Zealand hospitals [abstract]. Heart, Lung and Circulation 2004;13:230.
59. Ellis C, Gamble G, French J, et al. Management of patients admitted with an acute coronary syndrome in New Zealand: results of a comprehensive nationwide audit. N Z Med J 2004;117:U953.